Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 22

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
.0 million. The Company is required
to pay the Sales Agents a commission of 3% of the gross proceeds from the sale of shares. During
the six months ended June 30, 2025, the Company issued and sold 1,304,707 shares of common stock at an average price of $8.01 per
share under the ATM program. The aggregate net proceeds were approximately $10.1 million after commission expenses. At June 30, 2025,
the Company had $64.5 million of common stock available under the amended and restated at-the-market agreement.

Stock options

The following
table summarizes stock option activity during the six months ended June 30, 2025:

  (in thousands, except share and per share amounts)  Number of Shares   Weighted- average Exercise Price   Weighted- average Remaining Contractual Term (years)   Aggregate Intrinsic Value   Outstanding at January 1, 2025   7,203,307   $8.29    6.49   $1,218   Options granted   100,000   $7.88    10.0    -   Options exercised   -   $-    -    -   Options cancelled   (22,000)  $5.05    -    -   Outstanding at June 30, 2025   7,281,307   $8.29    6.03   $-   Exercisable at June 30, 2025   5,379,014   $8.78    4.94   $-  

During the three and six months ended June 30,
2025, the Company recognized stock-based compensation expense of approximately $1.5 million and $3.6 million, respectively, related to
the vesting of stock options. During the three and six months ended June 30, 2024, the Company recognized stock-based compensation expense
of approximately $2.3 million and $4.1 million, respectively, related to the vesting of stock options. As of June 30, 2025, there was
approximately $9.2 million of total unrecognized compensation cost related to non-vested stock options which is expected to be recognized
over a weighted-average period of 2.67 years